Core Viewpoint - WuXi AppTec has reported record-high revenue and profit figures for the fiscal year 2025, with basic earnings per share doubling to 6.70 CNY per share [1] Group 1: Financial Performance - The company achieved historical highs in revenue and profit across three metrics for the fiscal year 2025 [1] - The expected net profit attributable to shareholders for 2025 is projected to lead to a record cash dividend of over 5.7 billion CNY [1] Group 2: Shareholder Returns - WuXi AppTec has maintained a leading cash dividend ratio of 30% since its listing, reflecting its commitment to returning value to shareholders [1] - The anticipated rapid growth in net profit will be shared with shareholders through cash dividends [1] Group 3: Incentive Plans - The company has met the core unlocking conditions for its 2025 H-share incentive trust plan, with revenue targets set at 42 billion CNY and 43 billion CNY for additional stock grants [1] - A total of 2.5 billion HKD in equity incentives is set to be unlocked, aimed at fostering long-term development with core talent [1]

Group 1 - The company expects a revenue increase of approximately 15.84% for the fiscal year ending December 31, 2025, with projected revenue of about RMB 45,456.17 million [1] - The adjusted net profit attributable to shareholders is anticipated to be around RMB 14.957 billion, reflecting a year-on-year growth of approximately 41.33% [1] - The net profit attributable to shareholders is projected to reach approximately RMB 19.151 billion, representing a significant year-on-year increase of about 102.65% [1] Group 2 - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing) business model, enhancing capabilities and optimizing production processes to drive steady growth [2] - Non-recurring profit items impacting net profit include expected net gains of approximately RMB 4.161 billion from the sale of part of its stake in WuXi XDC Cayman Inc. and about RMB 1.434 billion from the sale of 100% stakes in two clinical research companies [2]

针对业绩预增的原因，药明康德表示，公司持续聚焦独特的"一体化、端到端"CRDMO（合同研究、开 发与生产）业务模式，紧抓客户对赋能需求的确定性，不断拓展新能力、建设新产能，持续优化生产工 艺和提高经营效率，推动业务持续稳健增长，高效极致赋能客户并致力于将更多新药、好药带给全球病 患。 北京商报讯（记者 丁宁）1月12日晚间，药明康德（603259）发布2025年度业绩预增公告显示，公司预 计2025年度实现营业收入约454.56亿元，同比增长约15.84%，其中持续经营业务收入同比增长约 21.4%。公司预计本期实现归属净利润约191.51亿元，同比增长约102.65%，其中包含了出售联营公司部 分股权以及剥离部分业务所获得的投资收益。 此外，本期非经常性损益项目对归属净利润的影响主要来自于出售持有的WuXi XDC Cayman Inc.部分 股权的净收益，预计约41.61亿元；以及出售所持有的上海康德弘翼医学临床研究有限公司和上海药明 津石医药科技有限公司100%股权的净收益，预计约14.34亿元。 ...

Core Viewpoint - WuXi AppTec (603259.SH) expects a net profit of 19.151 billion yuan for the year 2025, representing a year-on-year increase of approximately 103% [1] Financial Performance - The expected basic earnings per share for the period is approximately 6.70 yuan per share, reflecting a year-on-year growth of about 104.27% [1] - The increase in net profit includes gains from the sale of partial equity in an associate company and the divestiture of certain business segments [1] Business Strategy - The company continues to focus on its unique "integrated, end-to-end" CRDMO (Contract Research, Development, and Manufacturing Organization) business model [1] - WuXi AppTec is committed to meeting customer demands for empowerment, continuously expanding new capabilities, building new production capacity, and optimizing production processes to enhance operational efficiency [1] Non-Recurring Gains - The impact of non-recurring gains on the net profit attributable to shareholders mainly comes from the net gain of approximately 4.161 billion yuan from the sale of part of its stake in WuXi XDCCayman Inc. [1] - Additionally, the net gain from the sale of 100% equity in Shanghai Kangde Hongyi Medical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. is expected to be around 1.434 billion yuan [1]

Core Insights - Daxing District is experiencing a significant industrial transformation with the implementation of the "6+5+3" industrial development blueprint, leading to breakthroughs in the airport economy, health industry, hydrogen energy, software revenue, and commercial aerospace [1] Group 1: Industrial Development - The health industry in Daxing has doubled in scale over the past five years [1] - The hydrogen energy sector is leading the city, while the software industry has crossed two hundred billion revenue thresholds [1] - The commercial aerospace base is becoming a crucial support point for Beijing's "South Arrow North Star" layout [1] Group 2: Collaborative Development - Industrial collaboration is deemed essential for Daxing's growth, with a focus on creating a "1+1>2" win-win situation [2] - Daxing and Beijing Economic-Technological Development Area are working together in sectors like pharmaceutical R&D and intelligent transportation, facilitating mutual benefits [2] - Ongoing commercial cooperation is being promoted to enhance the synergy between the two regions [2] Group 3: Regional Cooperation - Daxing's strengths in R&D, headquarters economy, and high-end services complement Hebei's capabilities in equipment manufacturing and resource support [3] - Market-oriented cooperation pilot projects are being initiated based on the complementary advantages of both regions [3] - A pragmatic approach and a spirit of shared benefits are emphasized for effective regional collaboration [3] Group 4: Support for Innovation - Daxing's industrial policies and business environment provide robust support for technology innovation companies [3] - The establishment of an industrial guidance fund, in collaboration with leading investment institutions, amplifies financial leverage for innovation-driven manufacturing enterprises [3] - Companies in Daxing report a strong sense of benefit from the favorable business environment [3] Group 5: Green Transformation - Green transformation is identified as a key driver for high-quality development in Daxing [4] - Daxing has prioritized green standards in various plans, creating ample opportunities for renewable energy companies [4] - The focus on technological innovation, industrial upgrading, and urban construction is essential for achieving green development [4]

Core Viewpoint - Jingtai Holdings (02228) has seen a significant stock price increase, with a rise of nearly 8% during trading, currently up 6.12% at HKD 11.09, with a trading volume of HKD 1.26 billion [1] Group 1: Company Overview - Shenwan Hongyuan released a research report highlighting Jingtai Holdings' comprehensive coverage from physical computing to early-stage drug research automation, with core technologies including physical computing, AI, and robotics [1] - The company's business has expanded from AI drug development to a broader "AI4S" platform, indicating strong technological breadth and platform value [1] Group 2: Market Perception and Potential - The market's understanding of the technology transferability from AI pharmaceuticals to AI4S is insufficient, and there is a lack of recognition regarding the market potential of AI4S [1] - The company's wet and dry laboratories have formed a closed loop, effectively enhancing research and development efficiency, with long-term data accumulation from wet laboratories aiding in optimizing predictive models [1]

Group 1 - JPMorgan increased its stake in Kanglong Chemical (03759) by 1,456,225 shares at a price of HKD 19.388 per share, totaling approximately HKD 28.2333 million [2][4] - After the increase, JPMorgan's total shareholding in Kanglong Chemical reached approximately 15,810,300 shares, representing a stake of 5.24% [2][4]

1月5日，博济医药涨5.04%，截至发稿，报9.80元/股，成交3482.43万元，换手率1.28%，总市值37.80亿 元。 东财远见成长混合发起式A（018088）成立日期2023年4月11日，最新规模1203.03万。今年以来收益 28.7%，同类排名3300/8155；近一年收益28.7%，同类排名3300/8155；成立以来亏损14.27%。 东财远见成长混合发起式A（018088）基金经理为孙辰阳。 截至发稿，孙辰阳累计任职时间2年271天，现任基金资产总规模3383.61万元，任职期间最佳基金回报 38.97%， 任职期间最差基金回报-28.98%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 资料显示，博济医药科技股份有限公司位于广东省广州市天河区华观路1933号万科云广场A栋7楼，成 立日期2002年9月29日，上市日期2015年4月24日，公司主营业务涉及为医药企业和其他新药研发机构的 新药研发提供临床前研究服务、临床研究服务、 ...

Group 1 - Core viewpoint: WuXi AppTec is a leading integrated CRDMO provider, delivering efficient global services for the pharmaceutical and life sciences industry through continuous internal and external development [2][13] - The company has a highly experienced management team with a global perspective and is implementing an H-share incentive trust plan to attract and motivate key talent [2][13] - The CRDMO integration is expected to see a slight revenue decline in 2024, but the performance in the first half of 2025 is anticipated to be strong [2][13] Group 2 - The CXO industry is experiencing robust growth due to the long development times, high costs, and low success rates of drug development, leading to a trend of specialization in the pharmaceutical R&D service sector [3][14] - The rapid release of demand in China's pharmaceutical market, along with the increasing trend of refined specialization and the promotion of hierarchical diagnosis and treatment, is driving the prosperity of the CRO industry [3][14] - Pharmaceutical companies' demands for cost control and efficiency improvements are pushing CMO companies to upgrade to CDMO enterprises, resulting in steady growth in the global CDMO market, particularly in China [3][14] Group 3 - WuXi Chemistry offers integrated services with strong capital requirements and high customer stickiness, creating high barriers for CRDMO one-stop services [4][15] - The R&D business has a strong research capability, continuously attracting high-quality molecules, with 621 new molecules added to the D&M pipeline from Q1 to Q3 of 2025, including 250 molecules transitioning from R to D [4][15] - The D&M business is steadily growing in areas such as API services, formulation services, analytical services, and global regulatory affairs support, with a total of 3,430 small molecule D&M pipeline projects expected by the end of September 2025 [4][15] Group 4 - WuXi Testing provides testing solutions, although revenue has fluctuated in recent years [5][16] - The WIND platform offers integrated laboratory analysis and testing services, helping clients shorten drug development timelines while continuously enhancing capacity and global business layout [5][16] - The company has divested its clinical CRO and SMO services, focusing on core business areas, which has been impacted by market pricing factors leading to revenue declines in Q1 to Q3 of 2025 [5][16] Group 5 - WuXi Biology offers comprehensive biological services and solutions, covering all stages of drug discovery and major disease areas, while continuously building capabilities related to new molecular types [6][17] - The company is strengthening its capabilities in drug discovery hotspots and proactively expanding overseas business to efficiently drive the CRDMO business model [6][17] Group 6 - Profit forecast: Under a neutral scenario, the company expects net profit attributable to shareholders to be 15.86 billion, 15.22 billion, and 17.63 billion yuan for 2025-2027, with EPS of 5.32, 5.10, and 5.91 yuan per share, respectively [7][18] - The corresponding PE for 2025 is projected to be 17.44 times, with an initial coverage rating of "Accumulate" [7][18]

作者丨 杨婧雪 编辑丨 刘恒涛 图源 丨Midjourney 在创新药研发领域，临床试验一直是耗时最长、资金投入最大的环节之一。尽管早期药物发现阶段已经引入了人工智能（AI）筛 选、基因编辑等前沿技术，但在临床试验执行层面，依然保留着大量传统的线下人工作业模式，亟需数字化转型升级。 羚研创新是临床研发数字化这一赛道上的最先入局者之一。这家初创公司，主要业务方向是远程智能临床试验（DCT）平台及数 智化临床运营和内容服务。与行业巨头相比，羚研创新的切入点相对垂直，试图通过全流程整合的软件和AI服务的模式，解决临 床试验中因物理距离和人工操作带来的效率损耗。 跨界生物学+计算机 直击手工作业流程的顽疾 羚研创新创始人李高扬拥有生物学与计算机的复合背景，曾在拜耳、医渡科技等企业任职。在多年的从业经历中，他观察到医药 研发服务行业存在结构性的效率矛盾。 多项独立的国内外研究均表明，临床试验在药物研发总成本中占比50%-70%甚至更高。而在临床试验预算中，差旅、访视及现 场管理等人力成本，往往占据大部分比例。 而且主导临床试验服务的传统合同研究组织（CRO）服务商，大多采用按工时人力投入，并结合项目里程碑计费的商业模式 ...